Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World

Maria E Cabanillas; Naifa L Busaidy; Steven I Sherman

doi:10.1158/1078-0432.CCR-22-1710

Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World

Clin Cancer Res. 2022 Oct 3;28(19):4164-4166. doi: 10.1158/1078-0432.CCR-22-1710.

Authors

Maria E Cabanillas¹, Naifa L Busaidy¹, Steven I Sherman¹

Affiliation

¹ Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas.

PMID: 35895318
DOI: 10.1158/1078-0432.CCR-22-1710

Abstract

Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the holy grail in endocrine oncology. See related article by Weber et al., p. 4194.

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma* / drug therapy
Humans
Iodine Radioisotopes / therapeutic use
Prospective Studies
Protein Kinase Inhibitors / therapeutic use
Thyroid Neoplasms* / drug therapy

Substances

Iodine Radioisotopes
Protein Kinase Inhibitors